Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | W557_V559delinsF |
Impact List | indel |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT W557_V559delinsF results in a deletion of three amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 557 to 559, combined with the insertion of a phenylalanine (F) at the same site (PMID: 16226710). KIT W557_V559delinsF has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT W557_V559delinsF KIT mutant KIT exon11 KIT exon 11 del KIT W557_V559delinsF |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727438_54727443delGGAAGG |
cDNA | c.1670_1675delGGAAGG |
Protein | p.W557_V559delinsF |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017008178 | chr4:g.54727438_54727443delGGAAGG | c.1670_1675delGGAAGG | p.W557_V559delinsF | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727438_54727443delGGAAGG | c.1670_1675delGGAAGG | p.W557_V559delinsF | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727438_54727443delGGAAGG | c.1670_1675delGGAAGG | p.W557_V559delinsF | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54727438_54727443delGGAAGG | c.1670_1675delGGAAGG | p.W557_V559delinsF | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54727438_54727443delGGAAGG | c.1670_1675delGGAAGG | p.W557_V559delinsF | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727438_54727443delGGAAGG | c.1670_1675delGGAAGG | p.W557_V559delinsF | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT W557_V559delinsF | gastrointestinal stromal tumor | sensitive | Avapritinib | Preclinical - Pdx | Actionable | In a preclinical study, Ayvakit (avapritinib) treatment resulted in tumor regression in patient-derived xenograft models of gastrointestinal stromal tumor harboring KIT W557_V559delinsF (PMID: 29093181). | 29093181 |